JUBLINGREA Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,179 Cr
verified against source
Revenue YoY
12%
reported change
EBITDA
₹172 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Jubilant Ingrevia delivered its highest quarterly revenue and EBITDA in 14 quarters for Q4 FY26, with revenue of ₹1,179 crore (up 12% YoY) and EBITDA of ₹172 crore (up 11% YoY, up 26% QoQ). PAT came in at ₹86 crore, up 17% YoY. Performance was driven by strong volume growth across segments, with Specialty Chemicals posting ₹516 crore revenue at 27% margins for the sixth consecutive quarter, and Nutrition delivering ₹230 crore (up 21% YoY). The CDMO business saw 30-40% annual growth with a large agro contract now in commercial execution phase. The company commissioned its Bhilai CDMO plant in 14 months and completed the Remedyx acquisition for human nutrition premixes. Management targets at least 20% EBITDA growth for FY27 and expects sequential revenue and EBITDA improvement starting Q1 FY27, with the Gajola niacin plant commencing production in Q4 FY27. Working capital improved to 59 days, and net debt/EBITDA is at 2.99x. Key risks include customer concentration in CDMO (agro customer facing tough market conditions), acetic acid price volatility from Middle East disruptions, and FX headwinds from rupee depreciation on dollar-denominated contracts.
Colored figures show movement against the previous available record.
Guidance to track
- Management maintained its target of achieving at least 20% year-on-year EBITDA growth for FY27, expecting sequential improvement starting from Q1 itself as multiple growth drivers converge.
- Construction of the Gajola niacin plant is progressing well and will commence production in Q4 FY27, adding to the CDMO growth roadmap with further capacity for specialty chemicals.
- The company will continue investing behind growth with annual capex of ₹400-500 crore in FY27, with major investment going into the Gajola niacin plant which will be completed this year.
- The CDMO business, growing at 30-40% annually, is expected to accelerate further in FY27 with the large agro contract now in commercial execution phase and late-stage opportunities in the pipeline.
Risks flagged
- One of the key agro CDMO customers is going through tough market conditions. While the company has volume visibility for Q1 and contractual protection for any shortfall, the delayed volume confirmation creates execution uncertainty for FY27 projections.
- Acetic acid prices have sharply risen and are now falling. Management indicated it has minimized inventory impact through thoughtful purchasing at peak prices, but acknowledged potential impact could linger into early Q2 if prices continue declining. The pricing environment remains dynamic for the acetys segment.
- The $300 million agro CDMO contract was signed when USD/INR was around 84, now at 96. While management stated natural hedging through imports ($500 crore+ exports and similar imports) will limit impact, it acknowledged some positive benefit but not linear with the 12-rupee appreciation.
- Management noted pyridine prices are at rock bottom while beta-picoline prices are at multi-year highs. This counter-cyclical behavior balances margins but creates pricing uncertainty for the largest specialty chemicals product line (50,000 MT capacity at 90%+ utilization).
Key quotes
- We are pleased to report a healthy performance in Q4 and FY26. We had the highest quarterly revenue and EBITDA in Q4 FY26 when compared with last 14 quarters with healthy double-digit growth in both top line and bottom line.
- FY27 is the pivotal year in this journey where we are hoping to accelerate our growth starting with Q1 FY27 itself. We have made significant progress across all pillars of the journey leading to the creation of a strong foundation for future growth.
- The challenge in giving quarterly growth rates is because one contract moving up and down by a few weeks can make things look very staggered. But we will stick to our overall guidance of achieving at least 20% growth in EBITDA through the year.
Research modules